Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22807146 | 1.00 | NT5E (0.46) | NT5EPDE2A | |
| SCHEMBL29489846 | 1.00 | NT5E (0.46) | NT5EPDE2A | |
| SCHEMBL22807254 | 0.90 | NT5E (0.42) | NT5EPDE2A | |
| SCHEMBL22807184 | 0.87 | NT5E (0.55) | NT5EPDE2A | |
| SCHEMBL19948285 | 0.86 | NT5E (0.51) | NT5EPDE2A | |
| SCHEMBL22807253 | 0.86 | NT5E (0.41) | NT5EPDE2A | |
| SCHEMBL30115161 | 0.86 | NT5E (0.55) | NT5EPDE2A | |
| SCHEMBL22807286 | 0.86 | ADORA2A (0.46) | NT5EPDE2A | |
| SCHEMBL22807212 | 0.86 | ADORA2A (0.46) | NT5EPDE2A | |
| SCHEMBL29489883 | 0.86 | NT5E (0.41) | NT5EPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | disclosed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257429-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | NT5E 1/4885PDE2A 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.